详情页 - 四川省肿瘤医院知识库

资源类型：

文章类型：

作者：

Zhang, Li[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] * ; Yang, Yunpeng[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Qu, Song[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Li, Jin-Gao[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Hu, Chaosu[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Xu, Mingjun[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Li, Weidong[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Zhou, Ting[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15]

; Shen, Liangfang[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Wu, Hui[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Lang, Jin Yi[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15]

; Hu, Guangyuan[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Luo, Zhanxiong[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Fu, Zhichao[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Qu, Shenhong[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Zhang, Ben[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Yang, Qing[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Zhang, Xiaojing[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Zou, Jianjun[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Fang, Wenfeng[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ;

机构： [1]Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Dept Med Oncol,Canc Ctr, Guangzhou, Peoples R China [2]Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Dept Med Oncol,Canc Ctr, Guangzhou, Peoples R China [3]Guangxi Med Univ, Canc Hosp, Nanning, Peoples R China [4]Jiangxi Prov Tumor Hosp, Nanchang, Jiangxi, Peoples R China [5]Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China [6]Gannan Med Univ, Affiliated Hosp 1, Ganzhou, Peoples R China [7]Guangzhou Med Univ, Affiliated Oncol Hosp, Guangzhou, Peoples R China [8]Cent South Univ, Xiangya Hosp, Changsha, Peoples R China [9]Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Peoples R China [10]Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Radiat Oncol Key Lab Sichuan Prov, Dept Radiat Oncol,Sichuan Canc Ctr,Sch Med, Chengdu, Peoples R China [11]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China [12]Liuzhou Peoples Hosp, Liuzhou, Peoples R China [13]900 Hosp Joint Logist Support Force, Fuzhou, Peoples R China [14]Guangxi Zhuang Autonomous Reg Peoples Hosp, Nanning, Peoples R China [15]Jiangsu Hengrui Med Co Ltd, Shanghai, Peoples R China

出处：

DOI：

ISSN：

基金：

语种：

被引次数：

WOS：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

JCR分区：

出版当年[2021]版：

Q1 ONCOLOGY

最新[2023]版：

Q1 ONCOLOGY

第一作者：

第一作者机构： [1]Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Dept Med Oncol,Canc Ctr, Guangzhou, Peoples R China [2]Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Dept Med Oncol,Canc Ctr, Guangzhou, Peoples R China [3]Guangxi Med Univ, Canc Hosp, Nanning, Peoples R China [4]Jiangxi Prov Tumor Hosp, Nanchang, Jiangxi, Peoples R China [5]Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China [6]Gannan Med Univ, Affiliated Hosp 1, Ganzhou, Peoples R China [7]Guangzhou Med Univ, Affiliated Oncol Hosp, Guangzhou, Peoples R China [8]Cent South Univ, Xiangya Hosp, Changsha, Peoples R China [9]Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Peoples R China [10]Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Radiat Oncol Key Lab Sichuan Prov, Dept Radiat Oncol,Sichuan Canc Ctr,Sch Med, Chengdu, Peoples R China [11]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China [12]Liuzhou Peoples Hosp, Liuzhou, Peoples R China [13]900 Hosp Joint Logist Support Force, Fuzhou, Peoples R China [14]Guangxi Zhuang Autonomous Reg Peoples Hosp, Nanning, Peoples R China [15]Jiangsu Hengrui Med Co Ltd, Shanghai, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

Camrelizumab versus placebo combined with gemcitabine and cisplatin for recurrent or metastatic nasopharyngeal carcinoma: A randomized, double-blind, phase 3 trial.

文献详情